Clinical trials: Locally Advanced Pancreatic Carcinoma
Pancreatic Cancer, Pancreatic Carcinoma
Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation
This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation.The study consists of two stages I, Stage I ：explores the combination dose and the second phase; Stage II ：patients were…
- Trial name
- NCT07656376
- Testing
- DN022150+AG( Stage I ）, DN022150+AG（Stage II）
- Volunteers
- 465 people
- Sponsor
- Jiangxi Kvvit Pharmaceutical Co., Ltd.
Pancreatic Neoplasms Malignant, Malignant Neoplasm of Gall Bladder Non-resectable
Tomotherapy in Locally Advanced Gallbladder and Pancreatic Cancers
SUMMARY PROJECT TITLE: Concurrent chemo-radiation using Tomotherapy based IMRT in locally advanced Gallbladder and Pancreatic cancers: A Phase II study SPECIFIC OBJECTIVES: Primary To assess the radiological response by dose…
- Trial name
- NCT01118897
- Testing
- Tomotherapy
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Tata Memorial Hospital
Locally Advanced Pancreatic Adenocarcinoma
Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
The aim of this study is to demonstrate the efficacy of intensified and sequential chemotherapy (Gabrinox) comprising Gembrax regimen (Gemcitabine-Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) in…
- Trial name
- GABRINOX-ART (NCT04570943)
- Testing
- Gabrinox, MRI-GUIDED STEREOTACTIC RADIOTHERAPY
- Where
- 9 sites in France
- Volunteers
- 103 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Pancreatic Cancer
Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer
Previous reports suggest benefit of neoadjuvant chemoradiation treatment for borderline resectable pancreas cancer. This study is a multicenter prospective randomized phase II/III study of neoadjuvant chemoradiation with…
- Trial name
- NCT01458717
- Testing
- Neoadjuvant chemoradiation, Upfront surgery
- Where
- 5 sites in South Korea
- Volunteers
- 58 people
- Sponsor
- Seoul National University Hospital
Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer American Joint Committee on Cancer v8
PROACTIVE: Surgical Resection Outcomes in Locally Advanced and Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy
This clinical trial tests how well surgical resection after chemotherapy given before surgery to make the tumor smaller (neoadjuvant) works to treat pancreatic cancer that has spread to nearby tissue or lymph nodes (locally…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer American Joint Committee on Cancer v8, Unresectable Pancreatic Adenocarcinoma
- Trial name
- NCT06132087
- Testing
- Biospecimen Collection, Computed Tomography, Distal Pancreatectomy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Southern California
Pancreatic Cancer
Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer
Single compassionate use subject is an 83 year old woman with a history of lymph node positive breast cancer and recently diagnosed pancreatic cancer in May.
- Trial name
- NCT02851381
- Testing
- FG-3019
- Sponsor
- Jonsson Comprehensive Cancer Center
Pancreatic Cancer
Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
Research Hypothesis: Ipilimumab (an antibody that blocks negative signals to T cells) administered alone or in combination with a pancreatic cancer vaccine (allogeneic pancreatic tumor cells transfected with a GM-CSF gene), has…
- Trial name
- NCT00836407
- Testing
- Ipilimumab, Pancreatic Cancer Vaccine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
This single arm, multi-center phase II clinical trial will assess the safety and efficacy of FOLFIRINOX in the first-line setting in patients with unresectable locally advanced (ULA) and borderline resectable (BR) pancreatic…
- Trial name
- NCT01688336
- Testing
- FOLFIRINOX
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Pancreatic Cancer
Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)
In this prospective study, new diagnostic tools will be explored for patients with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (BR or LAPDA) who undergo neoadjuvant chemotherapy with FOLFIRINOX.
- Trial name
- PeRFormanCe (NCT05298722)
- Testing
- Imaging analysis of CT-scan and MRI with radiomics and genetic analysis of peripheral blood samples and questionnaires.
- Where
- 8 sites in Belgium, Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer
The purpose of this study is to evaluate the safety and efficacy of samuraciclib in patients with localized pancreatic cancer.
- Conditions
- Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07645651
- Testing
- Samuraciclib, Computed Tomography, Endoscopic Ultrasound Biopsy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Washington
Postoperative Complications
Clinical Outcomes of Surgery After Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
The purpose of this study was to investigate the clinical outcomes of patients with locally advanced pancreatic cancer (LA-PC) who underwent surgery after neoadjuvant chemotherapy (NACT) at Asan Medical Center's Department of…
- Trial name
- COSNALAP (NCT05888129)
- Testing
- surgery after neoadjuvant chemotherapy
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- Asan Medical Center
Pancreatic Adenocarcinoma Resectable, Pancreatic Adenocarcinoma Locally Advanced
Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with conventional treatments having little impact on disease course.
- Conditions
- Pancreatic Adenocarcinoma Resectable, Pancreatic Adenocarcinoma Locally Advanced, Pancreatic Adenocarcinoma Metastatic
- Trial name
- NEOPAX-001 (NCT01715142)
- Testing
- Gemcitabine, Abraxane
- Where
- 2 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Jean-Luc Van Laethem
Pancreatic Cancer
Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- SCALOP (NCT01032057)
- Testing
- capecitabine, gemcitabine hydrochloride, quality-of-life assessment
- Where
- 26 sites in United Kingdom
- Volunteers
- 114 people
- Sponsor
- Lisette Nixon
Pancreatic Cancer, Cancer
Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
This is a phase I trial to determine the maximum tolerated dose of carbon ion radiotherapy for the treatment of locally advanced, unresectable, pancreatic cancer.
- Trial name
- NCT03403049
- Testing
- Carbon Ion, Gemcitabine + Cisplatin, Gemcitabine + Capecitabine
- Where
- 2 sites in United States, China
- Volunteers
- 14 people
- Sponsor
- Montefiore Medical Center
Locally Advanced Pancreatic Cancer
Safety Study of Radiofrequency Ablation of Locally Advanced Pancreatic Cancer
The purpose of the study is to determine the safety of radiofrequency ablation of locally advanced pancreatic cancer that can not be surgically removed with the current standard procedures.
- Trial name
- RFA of LAPC (NCT01628458)
- Testing
- radiofrequency ablation (RFA)
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- UMC Utrecht
Metastatic Pancreatic Cancer
Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients
The majority patients diagnosed with pancreatic cancer have metastatic disease at the time of diagnosis. The prognosis is extremely poor with a 5-year survival rate of less than 5%.
- Trial name
- PACT-ACT-v6 (NCT02707159)
- Testing
- Nab paclitaxel / gemcitabine
- Where
- Norway
- Volunteers
- 70 people
- Sponsor
- Helse Stavanger HF
Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
This randomized phase II trial studies how well everolimus and octreotide acetate with or without bevacizumab works in treating patients with pancreatic neuroendocrine tumors that cannot be removed by surgery and have spread…
- Conditions
- Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor, Pancreatic Gastrinoma, Pancreatic Neuroendocrine Tumor G1
- Trial name
- NCT01229943
- Testing
- Bevacizumab, Everolimus, Octreotide Acetate
- Where
- 394 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Neoplasms
Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)
This clinical study is in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their pancreatic cancer.
- Trial name
- LAPACT (NCT02301143)
- Testing
- nab-Paclitaxel, Gemcitabine, Chemoradiation
- Where
- 42 sites in United States, Canada and 3 more
- Volunteers
- 107 people
- Sponsor
- Celgene
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur.
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
- Trial name
- innovaTV 207 (NCT03485209)
- Testing
- tisotumab vedotin, pembrolizumab, carboplatin
- Where
- 175 sites in United States, Canada and 5 more
- Volunteers
- 350 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
This phase II trial studies how well onvansertib in combination with gemcitabine and nab-paclitaxel works in treating patients with pancreatic ductal carcinoma (PDAC) that has spread to nearby tissue or lymph nodes (locally…
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
- Trial name
- NCT06398587
- Testing
- Onvansertib, Gemcitabine, Nab-paclitaxel
- Where
- United States
- Sponsor
- OHSU Knight Cancer Institute